Events

Time: 10:00AM - 4:00PM
Location: Saturn

Sign Up

Amgen will have two experts on site to discuss small molecule process development, protein expression, protein purification and characterization, and protein structural biology. An overview of Amgen’s Drug Substance Technologies organization will be featured along with a discussion on key features of synthetic process development spanning from early clinical studies to commercialization. Be sure to sign up for your slot today!

Shawn Walker, Director, Pivotal Drug Substance
Shawn leads the Synthetic Technologies & Engineering (STE) group within Amgen’s Process Development organization. STE is responsible for the development of efficient and cost-effective chemical manufacturing processes for Amgen’s synthetic and hybrid modalities, and for advancing continuous manufacturing technologies. The group's core capabilities include synthetic process design, process characterization, engineering, thermal hazards evaluation, modelling, crystallization and tech transfer. Shawn has been with Amgen since 2004 and his work experience spans pre-clinical & FIH drug substance development through to process validation & commercial launch.  

Xin Huang, Principal Scientist, Molecular Engineering
Xin leads the Structural Biology group within Amgen’s Discovery Research organization. The Structural Biology group is responsible for structural support (such as Structural Based Drug Discovery and Epitope Mapping) of both small and large molecule projects . The group's core capabilities include protein purification and characterization, crystallography, and more recently cryo-EM. Xin has been with Amgen since 2000 and his work experience spans both small molecule and large molecule therapeutics.  He has published over 40 papers including journals such asNature, Cancer Cell, Nature Structural & Molecular Biology, Journal of American Chemical Society, and Journal of Medicinal Chemistry.